Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not ...

Experts stress that obesity is a disease, not a lifestyle choice, and call for better access to pharmacological and surgical ...

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...

Obesity is a common health problem affecting a considerable (and growing) proportion of adult populations worldwide.1 Although overweight and obesity are usually diagnosed by anthropometry, such as ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Researchers analysed data from 150 adults with T1D, divided into semaglutide, tirzepatide, and control groups.